Discover our long-term partners
Servier is a global pharmaceutical group governed by a Foundation with a strong international presence in 150 countries and 22,500 employees worldwide. As an independent group, Servier is committed to therapeutic progress to server patient needs and invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. A leader in cardiology, Servier aims to become a renowned and innovative player in oncology. Its development is driven by a continuous focus on cardiovascular and metabolic diseases, oncology and immuno-inflammatory, and neurodegenerative diseases. To promote access to healthcare for all, the Group also offers a range of quality generic drugs covering most pathologies.
With Amgen Innovations, we are strengthening our commitment to healthcare and research players in France. Concretely, we act as a catalyst around three key actions that structure this unprecedented program: to undertake partnerships with start-ups to reinvent the health path, to support calls for research projects to discover the therapeutic innovations of tomorrow and to strengthen our support. to caregivers facing the challenges of their profession. Associating biological and technological progress with human and social sciences opens up the field of possibilities. Convinced of the richness of the French ecosystem in terms of innovation, through Amgen Innovations, we wish to contribute to the emergence of healthcare solutions that have meaning for patients and healthcare professionals.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Invest Securities is an independent brokerage company with a complementary business unit including brokerage, analysis office and issuer services. We provide solutions adapted to companies, institutional investors as well as to fund managers. Within Allinvest, Invest Securities benefits from the synergies of the finance company and is ranked as the leading listing sponsor on the Euronext and Euronext Growth markets.
ICOSA is an European IP Law firm with a business vision. Dedicated to Healthcare (from Pharma to medical device and AI-related inventions), Food and Environment, ICOSA helps to :
- Build-up IP Rights portfolio.
- Define strengths and weaknesses of patients under acquisition or funding.
- Get the most relevant information on patentability or freedom-to-operate.
With 45 employees, ICOSA is a lively and alert law firm, continuously adapting its high technical level (our Patent Attorneys are mostly PhD.) and IP skills to the purpose of the mission for which it is entrusted.
Our Super Gold Partner
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Our Gold Partner
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.
Our Silver Partners
Bpifrance, a public investment bank, is the trusted partner for entrepreneurs. Bpifrance finances businesses from the seed phase to transfer to stock exchange listing, through loans, guarantees and equity. Bpifrance accompanies firms developing export activites, in partnership with Business France and Coface, and provides support to their innovation projects. Bpifrance offers businesses the benefit of a powerful contact, on hand and able to respond efficiently. Bpifrance, whose two equal shareholders are the French State and the Deposits and Consignment Fund (Caisse des Dépôts), acts in support of public policy established by the State and the Regions.
Our Bronze Partners
Financière Arbevel wishes to pursue its development strategy by capitalizing on its DNA as a recognized stock-picker, while putting forth that it is first and foremost a “Research House that does management”. Financière has identified several growth drivers : an increasingly European environment, as evidenced by the launch of Pluvalva Europe Small Caps in December 2018 and the growth of our thematic funds focused on technological disruptions and biotechnology, a bond expertise centered around the issues of small- and mid-caps by developing synergies between credit and equity analysis, an all-cap management providing a flexible exposure ranging from large and mid caps through our Pluvalca AllCaps fund which has an excellent track record, the deployment of a non-listed franchise, with first a Life Sciences fund in October 2018, and later in bonds with the creation in 2019 of a private debt fund for Small and Medium companies that benefits from a European Investment Fund guarantee.
Dechert is a leading global law firm with 24 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients. Our team in France has more than 75 lawyers focused on regulatory, intellectual property, antitrust/competition, corporate/M&A, international arbitration, litigation, white collar crime and compliance, finance real estate, tax, labor and employment and financial services matters. Dechert’s life sciences team in France represents companies ranging from multinational giants to emerging companies involving all aspects of the life sciences industry, including pharmaceuticals, biotechnology, drug discovery, genomics, biopharmaceuticals, diagnostics, medical devices and health care. We also assist investment funds with life sciences investments. Read more
Euronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 1,900 listed issuers worth €5.6 trillion in market capitalisation as of end March 2021, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. There are currently 118 life science companies listed on Euronext, with a total market capitalisation of €43 billion. Euronext has thus become the world’s leading market for Medtech with 45 listed companies and the largest European market for biotech companies with 73 listed companies.